Hypersensitivity reactions occurred in 5.1% and 4.7% of Repatha ®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. Adverse Reactions in Primary Hyperlipidemia: The most common adverse reactions (>5% of patients treated with Repatha ® and more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.įrom a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha ®-treated and placebo-treated patients, respectively.If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with Repatha ®, treat according to the standard of care, and monitor until signs and symptoms resolve. Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, have been reported in patients treated with Repatha ®.Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha ®. Contraindication: Repatha ® is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha ®.As an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDL-C)-lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH) to reduce LDL-C.In adults with established cardiovascular disease to reduce the risk of myocardial infarction, stroke, and coronary revascularization.
0 Comments
Leave a Reply. |